Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1

Interventions

Rituximab 23Cyclophosphamide 17Bortezomib 15Filgrastim 14Peripheral Blood Stem Cell Transplantation 13fludarabine phosphate 10Etoposide 10Vincristine 8Radiotherapy 8Cyclosporine 8tanespimycin 7Prednisone 7alvocidib 6Vorinostat 6Ifosfamide 6Doxorubicin 6Cytarabine 6Melphalan 5Lenalidomide 5Busulfan 5temsirolimus 4sargramostim 4bryostatin 1 4Paclitaxel 4Methotrexate 4Magnetic Resonance Spectroscopy 4Interferon-alpha 4Gemcitabine 4Dexamethasone 4Carboplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, Mantle-Cell × ON 01910 × Clear all
NCT00861510 2019-12-03

A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
16 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Hairy Cell, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡